Medical education review; updated 10 November 2026. Regimens must be individualized and checked against local guidelines.
Overview
Tuberculosis (TB) treatment requires combinations of active drugs to cure disease and prevent acquired resistance. Regimen selection depends on drug-susceptibility testing, anatomic site, age, pregnancy, HIV status, prior treatment and local TB program guidance [1,2].
First-line pharmacology
- Isoniazid (H): hydrazide prodrug activated by mycobacterial KatG; blocks InhA-dependent mycolic-acid synthesis. Hepatic NAT2 acetylation varies by genotype. Risks: hepatitis and pyridoxine-responsive neuropathy.
- Rifampicin (R): rifamycin antibiotic inhibiting DNA-dependent RNA polymerase, with major enzyme/transporter induction and orange body fluids.
- Pyrazinamide (Z): nicotinamide analogue converted by PncA into pyrazinoic acid; mechanism is complex and incompletely characterized. Risks include hepatotoxicity and hyperuricemia; asymptomatic raised urate alone does not justify routine allopurinol prophylaxis.
- Ethambutol (E): inhibits arabinosyltransferases needed for mycobacterial cell wall synthesis; monitor visual acuity/color vision, and adjust for kidney dysfunction.
Drug-susceptible pulmonary TB
The conventional regimen is 2 months of HRZE followed by 4 months of HR when eligible [1,2]. A four-month rifapentine/moxifloxacin-containing regimen (2HPZM/2HPM) is an option for selected eligible patients with susceptible pulmonary TB; drug interactions and patient factors determine suitability [2]. Some children and adolescents with nonsevere TB may qualify for shorter evidence-based regimens under national protocols [1].
Drug-resistant TB
Management of rifampicin-resistant or multidrug-resistant TB must be guided by rapid molecular/phenotypic susceptibility testing and specialist TB services. WHO’s September 2026 recommendations prioritize individualized all-oral shorter regimens for eligible patients, including bedaquiline-based combinations and choices adjusted for disease severity and fluoroquinolone susceptibility; routine reliance on injectable aminoglycosides is outdated [1]. Never assemble drug-resistant TB treatment from an unverified list of second-line drugs.
Important newer agents
- Bedaquiline: inhibits mycobacterial ATP synthase; monitor QT interval and interactions.
- Pretomanid and delamanid: nitroimidazoles with antimycobacterial activity; specialist-led use.
- Linezolid: 50S ribosomal inhibitor; monitor marrow suppression, neuropathy and drug interactions.
- Moxifloxacin/levofloxacin: inhibit bacterial DNA gyrase; consider QT effects, tendon injury and chelation with polyvalent cations.
Interactions and monitoring
Rifampicin reduces exposure to many antiretrovirals, hormonal contraceptives, oral anticoagulants and other drugs; it is used to treat TB, not to accelerate HIV drug metabolism. Monitor symptoms and test for liver injury when indicated, renal function for renally cleared agents, vision with ethambutol and ECG where QT-prolonging regimens are used. Pyridoxine supplementation is important for isoniazid-treated patients at neuropathy risk. Use patient-centred adherence support and investigate missed doses or persistent positive cultures [1,2].
Latent TB infection
Preventive treatment for TB infection is distinct from active TB treatment. Short rifamycin-based regimens are often preferred when suitable after active disease is excluded; isoniazid preventive therapy is established, not experimental. Confirm eligibility, interactions and public-health guidance [2].
Key corrections
Isoniazid is not a nitroimidazole; ethambutol is not a quinoline carboxylate; rifapentine is not a metabolite of rifampicin. Modern resistant-TB treatment should not be presented as primarily injectable second-line therapy.
References
- World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment and care. 2nd ed. Geneva: WHO; 2026. ISBN: 9789240125124. Available from: https://www.who.int/publications/i/item/9789240125124
- Centers for Disease Control and Prevention. Treatment for drug-susceptible tuberculosis disease. Accessed 2026 Nov 10. Available from: https://www.cdc.gov/tb/hcp/treatment/tuberculosis-disease.html
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.